Loading
NASDAQHealthcareBiotechnology
Latest quote
$8.49
+$0.18 · +2.17%
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Previous close
$8.49
+$0.18 · +2.17%
After-hours
$8.27
−$0.22 · -2.59%
Sep 4, 7:55 PM ET
Regular session · ET · Market data may be delayed.
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Day range
Current $8.49
52-week range
Current $8.49
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
27
Expensive
Sentiment
58
Mixed
Risk
58
Elevated Risk
Momentum
68
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Day range
Current $8.49
52-week range
Current $8.49
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 228K USD | 229K USD | — | — | — |
| Gross profit | −228K USD | −229K USD | — | — | — |
| Research and development | 22.96M USD | 22.82M USD | 15.81M USD | 30.08M USD | 23.97M USD |
| Selling, general, and administrative | 31.87M USD | 16.25M USD | 11.44M USD | 10.72M USD | 9.13M USD |
| Operating expenses | 54.65M USD | 38.84M USD | 27.25M USD | 40.8M USD | 33.09M USD |
| Interest income | 1.5M USD | 2.36M USD | 825K USD | 199K USD | 17K USD |
| Interest expense | 819K USD | 2.18M USD | 2.85M USD | 1.79M USD | — |
| Depreciation and amortization | 228K USD | 229K USD | 228K USD | 236K USD | 250K USD |
| Operating income | −54.88M USD | −39.07M USD | −27.25M USD | −40.8M USD | −33.09M USD |
| Net income | −54.65M USD | −39.83M USD | −29.82M USD | −42.35M USD | −33.15M USD |
Company facts updated Sep 5, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$14.00
64.90% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 31, 2020 | 1:20 | — | — |
Stock split | May 24, 2018 | 1:10 | — | — |
Stock split | Aug 3, 2017 | 1:11 | — | — |
Stock split | Aug 21, 2008 | 1:18 | — | — |
Effective Jul 31, 2020
1:20
Effective May 24, 2018
1:10
Effective Aug 3, 2017
1:11
Effective Aug 21, 2008
1:18
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
